Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Docetaxel plus prednisone as a first-line chemotherapy ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis ...

and a corticosteroid as a first-line therapy for metastatic castration-resistant prostate cancer (mCRPC). However, the panel agreed with the FDA reviewer’s position that the regimen had not yet ...

Men with metastatic castration-resistant prostate cancer (mCRPC ... use of drugs known to reduce ICI efficacy, such as steroids and antibiotics. "Considering the prevailing negativity of multiple ...

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons.

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) for indication in combination with ...

AstraZeneca Pharma India has surrendered marketing authorization for Olaparib (Lynparza) in India due to commercial reasons. The drug is indicated for metastatic castration-resistant prostate cancer.